28 August 2024
Hemogenyx Pharmaceuticals
plc
("Hemogenyx Pharmaceuticals" or the
"Company")
Presentation at CBD S&T
Conference
Hemogenyx Pharmaceuticals plc (LSE:
HEMO), the clinical-stage
biopharmaceutical group developing treatments for cancers and viral
diseases, is pleased to announce its participation in the
2024 Chemical and Biological Defense Science
& Technology ("CBD
S&T")
Conference, which will be held on December
2-5, 2024, in Fort Lauderdale, FL.
The Company competed for a
presentation slot and was invited to present its work on its
proprietary Chimeric Bait Receptor ("CBR") platform for combating
viral infections. The presentation is entitled "Chimeric Bait Receptor (CBR) for Reprogramming of Myeloid
Cells to Target and Eliminate Emerging Viral
Infections".
The Company's CBR platform is an
advanced immunotherapy designed to program or redirect innate
immune cells, such as macrophages, to eliminate specific types of
cancer as well as to combat infections from both existing and
emerging viral threats. The Company's presentation at the CBD
S&T conference will focus on the use of the CBR platform for
combating viral infections.
Dr. Vladislav Sandler, CEO &
Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our
presentation at the CBD S&T conference will provide the Company
with an opportunity to further establish its unique position in the
rapidly evolving field of biodefense. It will also allow us to
exchange ideas with like-minded biodefense experts, potential
collaborators, and investors."
Enquiries:
|
Hemogenyx Pharmaceuticals plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
|
|
|
SP
Angel Corporate Finance LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
|
|
|
Peterhouse Capital Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
About Hemogenyx
Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a
publicly traded company (LSE: HEMO) headquartered in London, with
its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and
Immugenyx LLC, located in New York City at its state-of-the-art
research facility.
The Company is a clinical-stage
biopharmaceutical group developing new medicines and treatments for
life-threatening diseases. Hemogenyx Pharmaceuticals is developing
several distinct and complementary product candidates, as well as a
platform technology that it uses as an engine for novel product
development.